- Home
- IGI vs SKYE Comparison
IGI vs SKYE Comparison
Compare IGI & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGI
- SKYE
- Stock Information
- Founded
- IGI 2009
- SKYE 2012
- Country
- IGI United States
- SKYE United States
- Employees
- IGI N/A
- SKYE N/A
- Industry
- IGI Investment Managers
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- IGI Finance
- SKYE Health Care
- Exchange
- IGI Nasdaq
- SKYE Nasdaq
- Market Cap
- IGI 102.0M
- SKYE 121.8M
- IPO Year
- IGI N/A
- SKYE N/A
- Fundamental
- Price
- IGI $16.72
- SKYE $4.75
- Analyst Decision
- IGI
- SKYE Strong Buy
- Analyst Count
- IGI 0
- SKYE 5
- Target Price
- IGI N/A
- SKYE $14.75
- AVG Volume (30 Days)
- IGI 33.9K
- SKYE 410.9K
- Earning Date
- IGI 01-01-0001
- SKYE 11-06-2025
- Dividend Yield
- IGI 4.79%
- SKYE N/A
- EPS Growth
- IGI N/A
- SKYE N/A
- EPS
- IGI N/A
- SKYE N/A
- Revenue
- IGI N/A
- SKYE N/A
- Revenue This Year
- IGI N/A
- SKYE N/A
- Revenue Next Year
- IGI N/A
- SKYE N/A
- P/E Ratio
- IGI N/A
- SKYE N/A
- Revenue Growth
- IGI N/A
- SKYE N/A
- 52 Week Low
- IGI $15.13
- SKYE $1.14
- 52 Week High
- IGI $17.79
- SKYE $5.96
- Technical
- Relative Strength Index (RSI)
- IGI 48.79
- SKYE 68.46
- Support Level
- IGI $16.64
- SKYE $3.85
- Resistance Level
- IGI $17.09
- SKYE $4.16
- Average True Range (ATR)
- IGI 0.13
- SKYE 0.34
- MACD
- IGI -0.03
- SKYE 0.07
- Stochastic Oscillator
- IGI 27.45
- SKYE 85.27
About IGI Western Asset Investment Grade Defined Opportunity Trust Inc.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.